Apex Biotechnology Corp.

TWSE:1733 Voorraadrapport

Marktkapitalisatie: NT$2.9b

Apex Biotechnology Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Apex Biotechnology heeft een totaal eigen vermogen van NT$1.7B en een totale schuld van NT$5.0M, wat de schuld-eigenvermogensverhouding op 0.3% brengt. De totale activa en totale passiva bedragen respectievelijk NT$2.3B en NT$549.4M. De EBIT Apex Biotechnology is NT$109.2M waardoor de rentedekking -359.3 is. Het heeft contanten en kortetermijnbeleggingen van NT$432.6M.

Belangrijke informatie

0.3%

Verhouding schuld/eigen vermogen

NT$5.00m

Schuld

Rente dekkingsratio-359.3x
ContantNT$432.61m
AandelenNT$1.75b
Totaal verplichtingenNT$549.42m
Totaal activaNT$2.29b

Recente financiële gezondheidsupdates

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Recent updates

Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Aug 06
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around

Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Mar 21
Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings

Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Apr 17
Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business

Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Mar 30
Is Apex Biotechnology (TPE:1733) Using Too Much Debt?

Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Mar 10
Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?

Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

Feb 17
Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?

A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Jan 27
A Look At Apex Biotechnology's (TPE:1733) Share Price Returns

Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

Jan 06
Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture

These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Dec 16
These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely

Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Nov 22
Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$1.5B ) 1733 } overtreffen de korte termijn passiva ( NT$430.5M ).

Langlopende schulden: De kortetermijnactiva 1733 ( NT$1.5B ) overtreffen de langetermijnschulden ( NT$118.9M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 1733 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 1733 is de afgelopen 5 jaar gedaald van 25.2% naar 0.3%.

Schuldendekking: De schuld van 1733 wordt goed gedekt door de operationele kasstroom ( 5299% ).

Rentedekking: 1733 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Balans

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y